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SUMMARY
We aimed to investigate hepatitis C virus (HCV) epidemiology among hemodialysis (HD)
patients in the Middle East and North Africa (MENA). Our data source was an HCV biological
measures database populated through systematic literature searches. Descriptive epidemiologic
syntheses, effects meta-analyses and meta-regressions, and genotype analyses were conducted. We
analyzed 289 studies, including 106 463 HD patients. HCV incidence ranged between 0 and 100%
as seroconversion risk, and between 0 and 14·7 per 1000 person-years as incidence rate. The
regional pooled mean estimate was 29·2% (95% CI: 25·6–32·8%) for HCV antibody positive
prevalence and 63·0% (95% CI: 55·4–70·3%) for the viremic rate. Region within MENA, country
income group, and year of data collection were associated with HCV prevalence; year of data
collection adjusted odds ratio was 0·92 (95% CI: 0·90–0·95). Genotype diversity varied across
countries with four genotypes documented regionally: genotype 1 (39·3%), genotype 2 (5·7%),
genotype 3 (29·6%), and genotype 4 (25·4%). Our ﬁndings showed that one-third of HD patients
are HCV antibody positive and one-ﬁfth are chronic carriers and can transmit the infection.
However, HCV prevalence is declining. In context of growing HD patient population and
increasing HCV treatment availability, it is critical to improve standards of infection control in
dialysis and expand treatment coverage.
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INTRODUCTION
Viral hepatitis is the 7th leading cause of mortality
worldwide with hepatitis C virus (HCV) accounting
for about half of this mortality [1]. Though HCV
infection is a public health concern globally, the
Middle East and North Africa (MENA) is the most
affected region by this infection [1–3]. For 2015,
MENA was estimated to have the highest incidence
rate of all regions at 62·5 per 100 000 person-year,
second largest incidence at 409 000 new infections
per year, highest HCV antibody prevalence at 2·3%,
and largest number of chronically infected people at
15 million [2].
Recent breakthroughs in HCV treatment, notably
the introduction of highly effective direct-acting anti-
virals (DAA), have ushered a new era for controlling
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HCV and reducing its disease burden [4]. Global tar-
gets have been set to eliminate HCV and reduce its
mortality by 2030 [5, 6].
HCV is a blood borne pathogen transmitted paren-
terally such as through sharing of injections and use of
contaminated medical equipment [7]. Patients under-
going hemodialysis (HD) are at a higher risk of
HCV exposure due to sharing of dialysis machines
[8]. It has been estimated that HD increases the odds
of acquiring HCV by ﬁve folds [9]. Characterizing
HCV infection levels in HD patients and controlling
its transmission through this mode of exposure are
integral to improving the quality and healthcare util-
ization of HD. More speciﬁcally, this would lead to
the prevention of unnecessary health complications
such as liver disease and hepatic malignancies, and
to a reduction in associated healthcare costs [10–12].
Against this background, we aimed to characterize
HCV epidemiology among HD patients in the
MENA region by: (1) systematically describing the
evidence on HCV antibody incidence and prevalence
in this population; (2) estimating the mean country-
speciﬁc HCV prevalence in HD patients; (3) estimat-
ing HCV viremic rate in HD patients, that is the
prevalence of HCV chronic infection (HCV RNA
positivity) among antibody positive patients; (4) asses-
sing associations with HCV prevalence in this popula-
tion; and (5) assessing the frequency, distribution, and
diversity of HCV genotypes in HD patients. This
study was conducted under the umbrella of the
MENA HCV Epidemiology Synthesis Project, an
on-going effort to characterize HCV epidemiology
and inform key public health research, policy, and
programming priorities in MENA [13–19].
METHODOLOGY
Data source
Our source of data was the MENAHCV Epidemiology
Synthesis Project database. This database consists of
several sub-databases that include an HCV antibody
incidence database comprising 47 incidence studies
among 29 600 participants, an HCV antibody preva-
lence database comprising 2543 antibody prevalence
studies among 52 598 736 participants, an HCV RNA
prevalence (among antibody positive persons) database
comprising 178 RNA prevalence studies among 19 593
HCV antibody-positive participants, and an HCV
genotype frequency database comprising 338 HCV
genotype studies among 82 257 participants.
The MENA HCV Epidemiology Synthesis Project
database was compiled through systematic searches
of the literature [13, 15–17, 20–22] informed by the
Cochrane Collaboration handbook [23] and reporting
the ﬁndings using the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA)
guidelines [24]. The searched literature included inter-
national databases (PubMed and Embase), regional
databases, national databases, and the MENA HIV/
AIDS Epidemiology Synthesis Project database [25, 26],
in addition to gray literature comprised of public
health reports and routine data reporting, which are
available from the authors upon request. The system-
atic reviews used broad search criteria with no lan-
guage or year restrictions, to capture all publications
pertinent to HCV since the discovery of the virus in
1989 [27, 28]. The systematic searches screened for
duplicate studies and excluded them to avoid double
counting of any single study.
The deﬁnition of the MENA region in these
searches and in the present article included the 24
countries of Afghanistan, Algeria, Bahrain, Djibouti,
Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya,
Mauritania, Morocco, Oman, Pakistan, Palestine,
Qatar, Saudi Arabia, Somalia, Sudan, Syria,
Tunisia, the United Arab Emirates (UAE), and
Yemen.
For the purpose of the present study, we also
searched the literature (non-systematically) for studies
of the population proportion of HD patients in
MENA countries – that is the proportion of HD
patients among the whole population in a given coun-
try. For estimating the number of people undergoing
dialysis, the total population size in each country
was obtained from the United Nations World
Population Prospects database [29]. The MENA
region estimate was calculated as a weighted (by
population size) mean of available country measures.
Quantitative analyses
Meta-analyses
We conducted meta-analyses to estimate the country-
speciﬁc mean HCV antibody prevalence. We further
stratiﬁed HCV prevalence measures by year of publi-
cation and conducted meta-analyses for three different
but consecutive temporal durations to descriptively
examine changes in prevalence with time. Studies con-
sisting of a minimum of 20 participants were included.
We also conducted meta-analyses to estimate the
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country-speciﬁc mean viremic rate. Studies consisting
of a minimum of 10 antibody-positive participants
were included. In the event that the study reported
HCV prevalence by different strata, such as age and
sex, among others, the total sample size was replaced
with stratiﬁed measures whenever the sample size
requirement was fulﬁlled for each stratum.
Meta-analyses were conducted whenever we had
three or more measures to be pooled using a DerSimo-
nian–Laird random-effects model with inverse vari-
ance weighting [30]. The variance was stabilized
using the Freeman–Tukey type arcsine square-root
transformation [31]. Cochran’s Q test was implemen-
ted to assess evidence for heterogeneity in effect size;
a P-value < 0·1 was considered signiﬁcant [32, 33].
The I2 was calculated to assess the proportion of
between-study variation in effect size (HCV preva-
lence or HCV viremic rate) that is due to actual
differences in effect size between studies [32]. The
prediction interval was calculated to assess the distri-
bution of true effects around the estimated mean
[32, 34].
Meta-regressions
We conducted meta-regressions on HCV prevalence
studies to assess associations with HCV prevalence.
Four types of potential predictors were speciﬁed a
priori and included in the analyses: region within
MENA, country income group, year of data collec-
tion, and sample size. Factors with a P-value < 0·1
in univariable analyses were eligible for inclusion in
the ﬁnal multivariable model. Factors with a
P-value < 0·05 in the multivariable model were con-
sidered as signiﬁcant predictors.
The region variable consisted of seven strata based
on geographic proximity: Fertile Crescent (Iraq,
Jordan, Lebanon, Palestine, and Syria); Gulf
(Kuwait, Oman, Saudi Arabia, UAE, and Qatar);
Horn of Africa (Yemen and Sudan); Maghreb
(Algeria, Libya, Morocco, and Tunisia); Egypt; Iran;
and Pakistan. This classiﬁcation covers all MENA
countries with available HCV data in HD patients.
The income group variable stratiﬁed countries
according to their income group per World Bank clas-
siﬁcation [35]. Low middle-income countries included
Egypt, Morocco, Pakistan, Sudan, Syria, Tunisia, and
Yemen. Upper middle-income countries included
Algeria, Iran, Iraq, Jordan, Lebanon, Libya, and
Palestine. High-income countries included Kuwait,
Oman, Saudi Arabia, Qatar, and UAE.
For the year-of-data-collection variable, we im-
puted the missing observations using the median of
the observed values calculated by subtracting the
year of data collection from the year of publication
for each study. A sensitivity analysis was conducted
with missing values for the non-imputed observations.
The results were similar with no impact on statistical
signiﬁcance (Supplementary Table S1 on the
Cambridge Journals Online website).
Genotype diversity
We analyzed the regional and country-speciﬁc fre-
quency, distribution, and diversity of HCV genotypes
among HD patients. The regional analysis was con-
ducted based on actual frequency from available stud-
ies, and also as a weighted estimate by each country’s
population size. The frequency for each genotype was
calculated with individuals testing positive for mul-
tiple genotypes contributing separately to the sum of
cases for each genotype, as per earlier methodology
[36]. Genotype diversity was assessed using Shannon
Diversity Index [37].
Statistical analyses were conducted using R studio
version 3.3.2 [38] and StataSE version 13 [39].
RESULTS
HD in MENA
The population proportion of patients undergoing
HD varied across countries (Table 1). The lowest
reported was 250·2 per million population in
Bahrain, and the highest reported was 665·4 per mil-
lion population in Lebanon. Based on available popu-
lation proportions, we estimated the country-speciﬁc
number of patients undergoing HD (Table 1). The
lowest was 327 patients in Bahrain, and the highest
was 25 225 in Iran. The MENA region population
proportion was 383·6 per million population yielding
an estimate of 239 759 HD patients.
Scope of evidence
Out of the MENA HCV Epidemiology Synthesis
Project database, we identiﬁed 21 HCV incidence
measures among a total of 8857 HD patients
(Supplementary Table S2), 205 HCV antibody preva-
lence measures among a total of 92 341 HD patients
(Table 2), 31 HCV RNA prevalence measures
among a total of 3172 HCV antibody-positive HD
patients (Supplementary Fig. S1), and 31 HCV
HCV among hemodialysis patients 3245
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genotype frequency measures among a total of
2093 HCV RNA-positive HD patients (Table 6;
Supplementary Fig. S2).
Out of the 24 included countries, data were avail-
able from 19 countries. The number of data points
varied by country. Iran, Saudi Arabia, Tunisia, and
Egypt contributed the largest number of data points.
Several countries contributed as little as one data
point.
HCV antibody incidence among HD patients
Egypt (n= 6), Lebanon (n= 6), and Morocco (n= 4)
are the countries with the largest number of studies
reporting HCV incidence among HD patients
(Supplementary Table S2). Most studies had a
follow-up duration ranging from 6 to 36 months,
and reported incidence either as a risk of serocon-
version or as an incidence rate. Seroconversion risk
varied widely and was in the range of 0–100%.
Incidence rate also varied substantially and was in
the range of 0–14·7 per 1000 person-years. Incidence
varied extensively even within the same country. For
example, in Lebanon, HCV incidence rate varied
from 0 to 14·7 per 1000 person-years across different
geographical sites [120].
HCV antibody prevalence among HD patients
Iran (n= 41), Saudi Arabia (n= 39), and Egypt (n=
26) are the countries with the largest number of studies
reporting HCV prevalence among HD patients
(Table 2). HCV antibody prevalence varied widely
within and across countries and was in the range of
0–100% with a median of 26·5%. For example, in
Egypt, HCV prevalence varied from 10·0% to 100%
across different geographical sites at different times.
Table 3 shows the pooled mean estimate of HCV
prevalence by country, by temporal duration, and
for the region. The country-speciﬁc mean estimate
ranged from 7·3% (95% CI: 3·7–11·7%) in Lebanon
to 65·5% (95% CI: 56·5–74·1%) in Egypt. HCV preva-
lence was 51·6% (95% CI: 46·1–57·1%) in years of
publication 1989–1998, and decreased to 27·8%
(95% CI: 23·1–32·8%) in 1999–2008, and 18·8%
(14·5–23·5%) in 2009–2016.
The mean estimate for the region was 29·2% (95%
CI: 25·6–32·8%). Egypt, Syria, Saudi Arabia,
Yemen, Morocco, and Qatar had a mean estimate
exceeding 40%. There was strong evidence for hetero-
geneity in effect size (that is HCV prevalence) in all
countries (P4 0·01). The vast majority of the vari-
ation was due to variation in effect size rather than
chance (I2 > 50%). The prediction intervals conﬁrmed
substantial variation in effect size in each country.
Forest plots for the country-speciﬁc meta-analyses
can be found in Supplementary Fig. S3.
HCV viremic rate among HD patients
Tunisia (n = 13) is the country with the largest number
of studies reporting HCV viremic rate among HD
patients (Table 4). For the rest of the countries,
there were either few or no measures. HCV viremic
rate varied across studies and was in the range of
19·1–93·3% with a median of 65·4%. The pooled
mean estimate for HCV viremic rate across MENA
was 63·0% (95% CI: 55·4–70·3%). There was evidence
for heterogeneity in effect size estimates (here HCV
viremic rate) across the region with a P< 0·0001.
The I2 for the pooled estimate was indicative of the
variation being due to true differences in effect size
rather than chance (I2 = 94·0%). The prediction inter-
val conﬁrmed substantial variation in effect size.
Forest plot for the regional meta-analysis can be
found in Supplementary Fig. S1.
Associations with HCV antibody prevalence among
HD patients
Table 5 shows the results of the univariable and multi-
variable meta-regressions. Region, income group, and
year of data collection were associated with HCV anti-
body prevalence in the univariable analysis (P-value
Table 1. Population proportion of hemodialysis (HD)
in the Middle East and North Africa (MENA) [40]
Country
Prevalence of
HD (per million
population)
Total
population
Estimated
number of
individuals
on HD
Bahrain 250·2 1 306 000 327
Iran 322·8 78 144 000 25 225
Kuwait 403·2 3 753 000 1513
Lebanon 665·4 4 924 000 3276
Oman 285·9 4 236 000 1211
Qatar 330·6 2 172 000 718
Saudi Arabia 512·9 30 887 000 15 842
MENAa 383·6 625 023 000 239 759
a The population proportion of HD for the MENA region
was estimated as a weighted mean of available country
measures.
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Table 2. Studies reporting hepatitis C virus (HCV) antibody prevalence among hemodialysis patients across the
Middle East and North Africa
First author, year of publication
Year(s) of
data collection Study site Population
Sample
size
HCV
prev. (%)
Algeria (n= 3)
Algerian Ministry of Health, 2008 [41] 2008 – HD patients 2503 23·8
Afredj, 2009 [42] 1995 – HD patients 1225 42·0
Zitouni, 2010 [43] 2008–2009 Clinical setting HD patients 373 22·8
Egypt (n= 26)
Abdel Hady, 1999 [44] – Unspeciﬁed HD patients 96 27·1
Abdel-Wahab, 1994 [45] 1992 Clinical setting HD patients 78 46·2
Attia, 2010 [46] 2008–2009 Clinical setting HD patients 206 46·1
El Gohary, 1995 [47] 1990–1992 Clinical setting HD patients 108 70·4
El Sayed Zaki, 2013 [48] – Unspeciﬁed HD patients 30 10·0
El-Emshaty, 2011 [49] – Clinical setting HD patients 39 56·4
Elgohry, 2012 [50] – Clinical setting HD patients 25 72·0
Gohar, 1995 [51] – Unspeciﬁed HD patients 64 87·5
Goher, 1998 [52] – HD center/units Male HD patients on non
reused dialyzers
131 75·6
Goher, 1998 [52] – HD center/units Female HD patients on
non-reused dialyzers
39 79·5
Goher, 1998 [52] – HD center/units Male HD patients on
reused dialyzers
108 67·6
Goher, 1998 [52] – HD center/units Female HD patients on
reused dialyzers
57 66·7
Hammad, 2009 [53] 2008 Clinical setting HD patients 34 94·1
Hassan, 1993 [54] 1991–1993 Unspeciﬁed HD patients 105 73·3
Helaly, 2015 [55] 2012 HD center/units HD patients 100 34·0
Mouchiran, 1995 [56] – Unspeciﬁed Patients regularly
attending renal dialysis
units (controlled units)
250 68·0
Mouchiran, 1995 [56] – Unspeciﬁed Patients regularly
attending renal dialysis
units (not controlled
units)
100 98·0
Ibrahim, 2010 [57] 2007 Clinical setting HD patients 100 70·0
Ismail, 1994 [58] – Clinical setting HD patients for <1 year 25 72·0
Ismail, 1994 [58] – Clinical setting HD patients for >1 year 39 100
Kamal, 2013 [59] 2011 Clinical setting HD patients 170 60·6
Kandil, 2007 [60] 2004–2006 Clinical setting HD patients 31 51·6
Khodir, 2012 [61] 2011 Clinical setting HD patients 2351 35·0
Saddik, 1997 [62] – Clinical setting HD patients 50 72·0
Shatat, 2000 [63] 1999 Unspeciﬁed HD patients 65 78·5
Zahran, 2014 [64] – HD center/units HD patients 514 49·6
Iran (n= 41)
Aghakhani, 2009 [65] – Clinical setting HD patients 289 3·1
Alavian, 2015 [66] 2012 HD center/units HD patients 274 0·0
Ali, 2008 [67] 2005–2006 Clinical setting HD patients 93 24·7
Amiri, 2005 [68] 2001 HD center/units HD patients 298 24·8
Azarkar, 2009 [69] 2007 Clinical setting HD patients 30 0·0
Bozorghi, 2006 [70] 2004 Clinical setting Male HD patients 44 2·3
Bozorghi, 2006 [70] 2004 Clinical setting Female HD patients 45 8·9
Broumand, 2002 [71] – HD center/units HD patients 548 19·2
Dadgaran, 2005 [72] – HD center/units HD patients 393 17·8
Dadmanesh, 2015 [73] 2012–2013 Clinical setting HD patients 138 0·0
Eslamifar, 2007 [74] 2006 HD center/units HD patients 77 6·5
Ghadir, 2009 [75] 2008 HD center/units HD patients 90 21·1
Haghazali, 2011 [76] 2007 Clinical setting HD patients 76 7·9
HCV among hemodialysis patients 3247
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Table 2 (cont.)
First author, year of publication
Year(s) of
data collection Study site Population
Sample
size
HCV
prev. (%)
Hamissi, 2011 [77] 2009 Clinical setting Male HD patients 120 5·8
Hamissi, 2011 [77] 2009 Clinical setting Female HD patients 75 8·0
Jahromi, 2007 [78] 2006 Clinical setting HD patients 34 5·9
Joukar, 2011 [79] 2009 HD center/units Female HD patients 228 8·8
Joukar, 2011 [79] 2009 HD center/units Male HD patients 286 14·3
Kalantari, 2014 [80] 2010 HD center/units HD patients 499 5·2
Kassaian, 2011 [81] 2009 Clinical setting HD patients 800 2·1
Mahdavi, 2009 [82] 2005 HD center/units HD patients 2403 9·4
Mak, 2001 [83] – HD center/units HD patients 86 31·4
Makhlough, 2008 [84] 2006 HD center/units HD patients 186 11·3
Mansour-Ghanaei, 2009 [85] 2007 Clinical setting HD patients 163 10·4
Mousavi, 2014 [86] – HD center/units HD patients 47 4·3
Rostami, 2013 [87] 2010–2011 HD center/units Female HD patients 1704 0·9
Rostami, 2013 [87] 2010–2011 HD center/units Male HD patients 2259 1·7
Sabur, 2003 [88] 1999–2000 Clinical setting HD patients 140 26·4
Salehi, 2014 [89] 2008 HD center/units HD patients 40 10·0
Samarbaf-Zadeh, 2015 [90] – HD center/units HD patients 430 9·1
Samimi-Rad, 2008 [91] 2005 HD center/units Male HD patients 101 1·0
Samimi-Rad, 2008 [91] 2005 HD center/units Female HD patients 103 9·7
Seyraﬁan, 2006 [92] 2005 HD center/units HD patients 556 2·9
Somi, 2007 [93] 2006 HD center/units HD patients 462 14·9
Somi, 2014 [94] 2012 HD center/units HD patients 455 8·1
Taremi, 2005 [95] 2004 HD center/units HD patients 324 20·4
Taziki, 2008 [96] 2006 HD center/units HD patients 497 12·3
Taziki, 2008 [96] 2001 HD center/units HD patients 348 18·4
Toosi, 2007 [97] – Clinical setting HD patients 130 8·5
Zahedi, 2012 [98] 2010 HD center/units HD patients 228 3·1
Ziaee, 2013 [99] 2010 Clinical setting HD patients 41 0·0
Iraq (n= 16)
Abdul-Aziz, 2001 [100] 1999–2001 Central laboratory Male HD patients 62 0·0
Abdul-Aziz, 2001 [100] 1999–2001 Central laboratory Female HD patients 33 0·0
Abdullah, 2012 [101] 2010 Clinical setting HD patients 236 38·9
Abdullah, 2012 [102] 2005–2007 Clinical setting HD patients 80 28·7
Al-Dulaimi, 2012 [103] 2010–2011 Clinical setting HD patients 84 14·3
Al-Mashhadani, 2006 [104] 2002 Clinical setting HD patients 87 11·5
Hassan, 2008 [105] 1996–2001 Central laboratory HD patients 35 14·3
Khattab, 2008 [106] 2003–2005 Clinical setting Male HD patients 102 4·9
Khattab, 2008 [106] 2003–2005 Clinical setting Female HD patients 67 10·4
Khattab, 2010 [107] 2003–2008 Clinical setting Male HD patients 153 3·3
Khattab, 2010 [107] 2003–2008 Clinical setting Female HD patients 91 7·7
Mnuti, 2011 [108] 2008–2010 Clinical setting Male HD patients 58 39·6
Mnuti, 2011 [108] 2008–2010 Clinical setting Female HD patients 42 42·8
Ramzi, 2010 [109] 2009 Clinical setting Male HD patients 63 25·4
Ramzi, 2010 [109] 2009 Clinical setting Female HD patients 38 28·9
Shihab, 2014 [110] 2012–2013 Clinical setting HD patients 122 42·6
Jordan (n= 9)
Al-Jamal, 2009 [111] 2007–2008 Clinical setting Male HD patients 63 31·7
Al-Jamal, 2009 [111] 2007–2008 Clinical setting Female HD patients 57 24·5
Batchoun, 2011 [112] – Clinical setting Male HD patients 67 49·2
Batchoun, 2011 [112] – Clinical setting Female HD patients 67 46·3
Batieha, 2007 [113] 2003 National HD patients 1711 20·5
Bdour, 2002 [114] – Clinical setting HD patients 283 32·5
Ghunaimat, 2007 [115] – Clinical setting Male HD patients 130 43·8
Ghunaimat, 2007 [115] – Clinical setting Female HD patients 79 59·5
Said, 1995 [116] 1994 HD center/units HD patients 273 24·5
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Table 2 (cont.)
First author, year of publication
Year(s) of
data collection Study site Population
Sample
size
HCV
prev. (%)
Kuwait (n= 3)
Altawalah, 2015 [117] 2012 Clinical setting Kuwaiti HD patients 740 4·7
Altawalah, 2015 [117] 2012 Clinical setting Non-Kuwaiti HD
patients
625 8·2
El Reshaid, 1995 [118] 1994 Clinical setting HD patients 232 40·0
Lebanon (n= 9)
Abdelnour, 1997 [119] – Clinical setting HD patients 108 15·7
Abou Rached, 2016 [120] 2010–2012 HD center/units HD patients in Beirut 559 3·6
Abou Rached, 2016 [120] 2010–2012 HD center/units HD patients in Mount
Lebanon
1632 4·5
Abou Rached, 2016 [120] 2010–2012 HD center/units HD patients in Beqaa 394 5·6
Abou Rached, 2016 [120] 2010–2012 HD center/units HD patients in South
Lebanon
339 7·1
Abou Rached, 2016 [120] 2010–2012 HD center/units HD patients in North
Lebanon
757 5·0
Abou Rached, 2016 [120] 2010–2012 HD center/units HD patients in Nabatieh 88 0·0
Mourani, 1999 [121] 1997 Clinical setting HD patients 20 15·0
Naman, 1996 [122] – Clinical setting HD patients 317 27·0
Libya (n= 5)
Alashek, 2010 [123] 2009 HD center/units HD patients 749 25·1
Alashek, 2012 [124] – HD center/units HD patients 2410 12·0
Daw, 2002 [125] 1999–2001 – HD patients 200 20·5
El-Zouki, 1993 [126] – Clinical setting HD patients 47 42·5
Elzouki, 1995 [127] – Clinical setting HD patients 153 21·0
Morocco (n= 7)
Benani, 1997 [128] – HD center/units HD patients 49 48·9
Benjelloun, 1996 [129] – HD center/units HD patients 114 35·1
Boulaajaj, 2005 [130] 1983–2002 Clinical setting HD patients 186 76·0
Foullous, 2015 [131] – HD center/units HD patients 630 30·8
Lioussﬁ, 2014 [132] 2009 HD center/units Patients on peritoneal
dialysis
38 8·0
Lioussﬁ, 2014 [132] 2009 HD center/units Patients on HD 67 60·0
Sekkat, 2008 [133] 2003–2004 HD center/units HD patients 303 68·3
Oman (n= 1)
Al-Dhahry, 1992 [134] 1991 Clinical setting HD patients 102 26·5
Pakistan (n= 7)
Ali, 2011 [135] – – HD patients 25 28·0
Chishti, 2015 [136] 2010–2011 Clinical setting HD patients 200 29·0
Gul, 2003 [137] 1999 Clinical setting HD patients 50 68·0
Khan, 2011 [138] 2010 Clinical setting HD patients 384 29·2
Khokhar, 2005 [139] 2002–2003 Clinical setting HD patients 97 23·7
Mahmud, 2014 [140] 2012–2013 Mixed setting HD patients 189 16·4
Mumtaz, 2009 [141] 2008 Clinical setting HD patients 50 28·0
Palestine (n= 12)
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Hebron 177 7·3
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Ramallah 135 3·7
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Nablus 174 2·9
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Beit Jala 93 8·6
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Tulkarem 71 5·6
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Qalqelia 44 15·9
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Jenin 117 15·4
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Jericho 25 4·0
Al Zabadi, 2016 [142] 2014 HD center/units HD patients in Salfeet 32 9·4
Dumaidi, 2014 [143] 2012–2013 Clinical setting HD patients in Jenin 87 41·4
Dumaidi, 2014 [143] 2012–2013 Clinical setting HD patients in Tulkarem 59 6·8
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Table 2 (cont.)
First author, year of publication
Year(s) of
data collection Study site Population
Sample
size
HCV
prev. (%)
El-Kader, 2010 [144] 2007 Clinical setting HD patients 246 17·9
Qatar (n= 1)
Abboud, 1995 [145] – Clinical setting HD patients 130 44·6
Saudi Arabia (n= 39)
Al Ghamdi, 2001 [146] 1997 Clinical setting HD patients 56 57·0
Al Jiffri, 2003 [147] 1991 Clinical setting HD patients 248 72·6
Al Mugeiren, 1992 [148] – Clinical setting HD patients 20 45·0
Al Muhanna, 1995 [149] – Clinical setting HD patients 162 43·2
Al Nasser, 1992 [150] – Clinical setting Male HD patients 40 42·5
Al Nasser, 1992 [150] – Clinical setting Female HD patients 26 50·0
Al Saran, 2014 [151] 2009 Clinical setting HD patients 144 27·8
Al Shohaib, 1995 [152] 1992 Clinical setting HD patients 139 52·5
Alsaran, 2009 [153] 2007–2008 Clinical setting HD patients 83 33·0
Ayoola, 1991 [154] – Clinical setting Male HD patients 33 42·5
Ayoola, 1991 [154] – Clinical setting Female HD patients 41 41·5
Bahakim, 1991 [155] 1990 Clinical setting HD patients 65 26·1
Bernieh, 1995 [156] 1991 Clinical setting HD patients 94 60·0
Fakunle, 1991 [157] – Clinical setting Nationals HD patients 113 48·7
Fakunle, 1991 [157] – Clinical setting Expatriates HD patients 77 61·0
Huraib, 1995 [158] – HD center/units HD patients 1147 68·0
Hussein, 1994 [159] 1993 Clinical setting HD patients 67 40·0
Hussein, 2007 [160] 2003 Clinical setting HD patients 180 18·9
Karkar, 2006 [161] – Clinical setting HD patients 265 29·0
Kashem, 2002 [162] – Clinical setting HD patients 75 46·0
Kashem, 2003 [163] 2002 Clinical setting HD patients 90 46·7
Kumar, 1997 [164] 1993–1996 Clinical setting HD patients 47 51·1
Mitwalli, 1992 [165] – Clinical setting HD patients 36 22·2
Mitwalli, 2000 [166] 1997 Clinical setting HD patients 109 54·1
Saran, 2011 [167] 2009 Clinical setting HD patients 146 24·1
Saxena, 2001 [168] – Clinical setting HD patients 189 43·9
Saxena, 2003 [169] 1995–2000 Clinical setting Male HD patients 99 49·5
Saxena, 2003 [169] 1995–2000 Clinical setting Female HD patients 97 33·0
Saxena, 2003 [170] 1995–2000 Clinical setting Male HD patients 91 38·5
Saxena, 2003 [170] 1995–2000 Clinical setting Female HD patients 98 49·0
Saxena, 2004 [171] 1995–2000 Clinical setting Male HD patients 86 62·8
Saxena, 2004 [171] 1995–2000 Clinical setting Female HD patients 86 37·2
Shaheen, 1995 [172] – Clinical setting HD patients 408 72·3
Shobokshi, 2003 [173] 1998–2002 Clinical setting HD patients 29 054 55·7
Souqiyyeh, 1995 [174] 1993–1994 Clinical setting HD patients 1392 54·0
Souqiyyeh, 2001 [175] 2000 HD center/units HD patients 6694 50·0
Soyannwo, 1996 [176] 1992 Clinical setting Male HD patients 47 53·2
Soyannwo, 1996 [176] 1992 Clinical setting Female HD patients 49 46·9
Tashkandy, 2012 [177] 2000–2004 Clinical setting HD patients 1357 78·2
Sudan (n= 3)
El-Amin, 2007 [178] 2005 HD center/units HD patients 236 23·7
Gasim, 2012 [179] 2010 HD center/units HD patients 353 8·5
Suliman, 1995 [180] 1994 HD center/units HD patients 46 34·9
Syria (n = 5)
Abdulkarim, 1998 [181] – HD center/units HD patients 120 75·0
Othman, 2001 [182] 1996 Clinical setting Male HD patients 80 53·7
Othman, 2001 [182] 1996 Clinical setting Female HD patients 59 42·4
Moukeh, 2009 [183] 2006 Clinical setting Male HD patients 280 53·9
Moukeh, 2009 [183] 2006 Clinical setting Female HD patients 270 54·8
Tunisia (n= 14)
Ayed, 2003 [184] 2001 HD center/units HD patients in Tunis 1394 22·2
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< 0·1 for all three variables). Sample size was not asso-
ciated with HCV prevalence (P-value > 0·7).
In the ﬁnal multivariable analysis, region and year
of data collection were included, but income group
was not due to collinearity. The model explained
54·48% of the variation. Relative to the Fertile
Crescent, the odds (for higher HCV prevalence) was
much larger in Egypt; adjusted odds ratio (AOR) of
7·43 (95% CI: 4·44–12·44). It was also higher in
Pakistan (AOR= 2·47; 95% CI: 1·07–5·69) and the
Gulf region (AOR= 1·77; 95% CI: 1·08–2·90), but
lower in Iran (AOR= 0·38; 95% CI: 0·24–0·58).
Importantly, the AOR for the year of data collection
was 0·92 (95% CI: 0·90–0·95) indicating declining
HCV prevalence in HD patients year by year.
Risk factors for HCV infection among HD patients
Few studies assessed risk factors for HCV infection
among HD patients. Duration and frequency of dialysis
and exposure to blood transfusions were the most com-
monly reported risk factors [45, 51, 52, 62, 109, 182].
HCV genotype and subtype distribution among HD
patients
Table 6 shows the frequency, distribution, and
Shannon Diversity Index of HCV genotypes among
HD patients. Supplementary Fig. S2 also shows the
distribution of HCV genotypes and subtypes.
The vast majority (92·3%) of viremic HD patients
were infected by a single strain (Supplementary
Fig. S2). At the regional level, four HCV genotypes
were documented in HD patients: genotype 1
(68·8%), genotype 2 (9·6%), genotype 3 (7·9%), and
genotype 4 (13·5%). Weighted by country population
size, the regional genotype distribution was: genotype
1 (39·3%), genotype 2 (5·7%), genotype 3 (29·6%), and
genotype 4 (25·4%). No cases of genotypes 5, 6, and 7
were reported.
Genotype 1 was commonly found in Morocco
(100%), Tunisia (77·3%), Jordan (73·3%), Syria
(60·7%), Iran (55·7%), Bahrain (55·5%), Iraq
(51·5%), and Saudi Arabia (46·8%). It was also com-
mon in Lebanon (28·1%), Pakistan (22·2%), and
Egypt (16·1%).
Table 2 (cont.)
First author, year of publication
Year(s) of
data collection Study site Population
Sample
size
HCV
prev. (%)
Ayed, 2003 [184] 2001 HD center/units HD patients in the
Northwestern region
358 15·4
Ayed, 2003 [184] 2001 HD center/units HD patients in the
Northern region
279 15·7
Ayed, 2003 [184] 2001 HD center/units HD patients in the
Northeastern region
199 30·1
Ayed, 2003 [184] 2001 HD center/units HD patients in the
central region
1314 18·5
Ayed, 2003 [184] 2001 HD center/units HD patients in the
Southern region
796 14·6
Ben Othman, 2004 [185] 2000–2002 HD center/units HD patients in Sousse 143 29·4
Ben Othman, 2004 [185] 2000–2002 HD center/units HD patients in Monastir 47 31·9
Ben Othman, 2004 [185] 2000–2002 HD center/units HD patients in Mahdia 86 38·4
Hmaied, 2006 [186] 2001–2003 HD center/units HD patients 395 20·0
Hachicha, 1995 [187] – HD center/units HD patients 235 36·6
Hmida, 1995 [188] – HD center/units HD patients 235 45·1
Jemni, 1994 [189] – HD center/units HD patients 63 42·0
Sassi, 2000 [190] – HD center/units HD patients 58 46·5
United Arab Emirates (n= 1)
El Shahat, 1995 [191] 1991–1993 Clinical setting HD patients 262 24·0
Yemen (n= 3)
Aman, 2015 [192] 2000–2013 HD center/units HD patients 219 40·2
Haidar, 2002 [193] 1997–1999 Clinical setting HD patients 30 40·0
Selm, 2010 [194] 2007 Clinical setting HD patients 51 62·7
HD, Hemodialysis; Prev., Prevalence.
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Table 3. Pooled mean estimate for hepatitis C virus (HCV) antibody prevalence among hemodialysis patients across countries of the Middle East and North
Africa
Country
Studies Samples
HCV Prevalence
across studies
Pooled HCV
prevalence Heterogeneity measures
Total N Total N Range (%) Median Mean (%) 95% CI Qa (P-value) I2b (95% CI)
Prediction
intervalc (%)
Algeria 3 4101 22·8–42·0 23·8 29·3 17·4–42·7 133·7 (P< 0·0001) 98·5 (97·4–99·1) 0·0–100
Egypt 26 4915 10·0–100 69·0 65·5 56·5–74·1 809·1 (P< 0·0001) 96·9 (96·2–97·5) 18·9–98·6
Iran 41 15 140 0–31·4 8·5 9·2 5·9–10·8 1076·5 (P< 0·0001) 96·3 (95·6–96·9) 0·0–29·4
Iraq 16 1353 0–42·9 14·3 16·6 9·0–25·7 248·2 (P< 0·0001) 94·0 (91·6–95·6) 0·0–62·1
Jordan 9 2730 20·5–59·5 32·5 36·1 27·4–45·2 120·7 (P< 0·0001) 93·4 (89·5–95·8) 9·0–69·1
Kuwait 3 1597 4·7–40·0 8·2 14·9 2·8–34·1 155·8 (P< 0·0001) 98·7 (97·8–99·2) 0·0–100
Lebanon 9 4214 0–27·0 5·6 7·3 3·7–11·7 159·0 (P< 0·0001) 95·0 (92·3–96·7) 0·0–27·1
Libya 5 3559 12·0–42·5 21·0 22·5 14·2–31·9 95·1 (P< 0·0001) 95·8 (92·7–97·6) 0·6–61·2
Morocco 7 1387 8·0–76·0 49·0 46·4 28·5–64·7 239·4 (P< 0·0001) 97·5 (96·3–98·3) 0·2–98·1
Pakistan 7 995 16·4–68·0 28·0 30·4 21·7–39·9 49·4 (P< 0·0001) 87·8 (77·3–93·5) 5·7–63·5
Palestine 12 1260 2·9–41·4 8·0 10·3 5·6–16·2 93·8 (P< 0·0001) 88·3 (81·4–92·6) 0·0–36·8
Saudi Arabia 39 43 250 18·9–78·2 46·9 47·4 43·7–51·1 998·1 (P< 0·0001) 96·2 (95·5–96·8) 26·8–68·4
Sudan 3 635 8·5–34·9 23·7 20·4 7·6–37·2 36·4 (P< 0·0001) 94·5 (87·3–97·6) 0·0–100
Syria 5 809 42·4–75·0 53·9 56·6 47·5–65·5 24·2 (P< 0·0001) 83·5 (62·6–92·7) 24·7–85·7
Tunisia 14 5602 14·6–46·5 29·8 27·4 22·6–32·5 194·4 (P< 0·0001) 93·3 (90·4–95·3) 10·3–48·9
Yemen 3 300 40·0–62·7 40·2 47·4 32·7–62·3 8·6 (P= 0·010) 76·8 (24·2–92·9) 0·0–100
Oman 1 102 – – 26·5 18·2–36·1 – – –
Qatar 1 130 – – 44·6 35·9–53·6 – – –
UAE 1 262 – – 24·4 19·3–30·1 – – –
Pooled HCV prevalence stratiﬁed
by temporal duration
1989–1998 50 8964 15·7–100 46·5 51·6 46·1–57·1 1235·3 (P< 0·0001) 96·0 (95·4–96·6) 16·0–86·3
1999–2008 69 53 500 0·0–78·5 23·8 27·8 23·1–32·8 7325·6 (P< 0·0001) 99·1 (99·0–99·1) 0·8–71·6
2009–2016 86 29 877 0·0–94·1 9·7 18·8 14·5–23·5 7941·1 (P< 0·0001) 98·9 (98·8–99·0) 0·0–68·8
All countries 205 92 341 0–100 26·5 29·2 25·6–32·8 26 145·8 (P< 0·0001) 99·2 (99·2–99·3) 0·0–82·0
CI, Conﬁdence interval; UAE, United Arab Emirates.
aQ: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.
b I2: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.
c Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.
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Table 4. Pooled mean estimate for hepatitis C virus (HCV) viremic rate among hemodialysis patients across countries of the Middle East and North Africa.
HCV viremic rate is the prevalence of HCV chronic infection (HCV RNA positivity) among antibody-positive persons
Country
Studies Samples
HCV RNA prevalence
among antibody
positive persons
Pooled HCV viremic
rate Heterogeneity measures
Total N Total N Range (%) Median Mean (%) 95% CI Qa (P-value) I2b (95% CI) Prediction intervalc (%)
Iran 4 219 48·6–64·3 52·3 51·1 44·3–57·9 1·3 (P= 0·7) 0·0 (0·0–65·0) 36·4–68·8
Iraq 2 144 26·1–61·5 43·8 38·9 30·9–47·4 – – –
Jordan 1 92 – – 31·5 22·2–42·0 – – –
Lebanon 2 63 30·4–65·0 47·7 39·7 27·6–52·8 – – –
Libya 1 32 – – 72·0 53·2–86·2 – – –
Morocco 4 309 48·9–70·0 59·7 57·9 49·2–66·5 5·3 (P= 0·1) 43·5 (0·0–81·1) 27·0–85·9
Pakistan 1 25 – – 28·0 12·1–49·4 – – –
Palestine 2 290 19·1–84·1 51·6 29·0 28·8–34·5 – – –
Syria 1 56 – – 87·5 75·9–94·8 – – –
Tunisia 13 1942 51·0–93·3 76·2 75·1 69·6–80·2 61·9 (P < 0·0001) 80·6 (67·8–88·3) 54·6–91·1
All countries 31 3172 19·1–93·3 65·4 63·0 55·4–70·3 499·9 (P< 0·0001) 94·0 (92·4–95·2) 21·7–95·5
HCV, Hepatitis C virus; RNA, Ribonucleic acid.
aQ: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.
b I2: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.
c Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.
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Genotype 4 was commonly found in Egypt (83·9%),
Saudi Arabia (50·0%), Iraq (45·4%), and Lebanon
(40·6%). It was also present in the rest of the countries
apart from Morocco. Pakistan was the only country
where genotype 3 was the most common genotype
(62·2%). Genotype 3 was also common in Iran
(39·4%), but otherwise rare in the rest of the countries.
Genotype 2 was common in Bahrain (33·3%) and
Lebanon (25·0%), and somewhat common in Pakistan
(13·3%) and Tunisia (11·8%), but otherwise rare.
For genotype 1, subtype 1a and 1b were commonly
observed in MENA (Supplementary Fig. S2). Subtypes
2a, 2b, 2c, 3a, 3b, and 4a were also detected in this
region. Combinations of the above genotypes and
subtypes were observed among multiply infected
individuals.
Genotype diversity varied across countries. It was
highest in Lebanon with a relative Shannon
Diversity Index of 63·7% (score: 1·24 out of a max-
imum of 1·95) and lowest in Morocco 0·0% (score:
0·0 out of a maximum of 1·95). For the region as a
whole, the relative Shannon Diversity Index was
49·1% (score: 0·95 out of a maximum of 1·95) for
the unweighted analysis, and 63·9% (score: 1·24 out
of a maximum of 1·95) for the weighted analysis by
country population size.
DISCUSSION
Through a comprehensive investigation of HCV epi-
demiology among HD patients in MENA, we found
that there is ongoing and considerably high HCV inci-
dence in this population across the region. However,
the incidence rate varied between countries and across
different settings within the same country
(Supplementary Table S2). We also found high
HCV prevalence in HD patients, with the prevalence
varying substantially across the region and within
each country. About one-third (29·2%) of HD patients
have already been infected with HCV (Table 3), with
two-thirds of them (63·0%) being chronic carriers
(Table 4) that can potentially transmit the infection
to other patients through dialysis. We also found sub-
stantial diversity of HCV genotypes in HD patients,
with genotype 1 being the most common at the
regional level (Table 6). Importantly, we found that
HCV prevalence in HD patients is on a declining
trend (Tables 3 and 5).
Table 5. Univariable and multivariable meta-regression models for hepatitis C virus (HCV) antibody prevalence
among hemodialysis patients across the Middle East and North Africa
Number of studies
Univariable analysis Multivariable analysisa
OR (95% CI) P-value AOR (95% CI) P-value
Region
Fertile Crescentb 51 1·0 – 1·0 –
Egypt 26 11·15 (6·49–19·16) 0·000 7·43 (4·44–12·44) 0·000
Gulfc 45 3·85 (2·43–6·10) 0·000 1·77 (1·08–2·90) 0·022
Horn of Africad 6 2·48 (0·94–6·55) 0·065 1·82 (0·74–4·46) 0·189
Iran 41 0·37 (0·23–0·59) 0·000 0·38 (0·24–0·58) 0·000
Maghrebe 29 2·30 (1·36–3·88) 0·002 1·47 (0·89–2·43) 0·130
Pakistan 7 2·32 (0·93–5·74) 0·068 2·47 (1·07–5·69) 0·033
Income groupf
LMIC 65 1·0 – – –
UMIC 95 0·12 (0·08–0·18) 0·000 – –
HIC 45 0·78 (0·49–1·24) 0·303 – –
Year of data collection 205 0·89 (0·87–0·91) 0·000 0·92 (0·90–0·95) 0·000
Sample size 205 1·00 (0·99–1·00) 0·677 – –
OR, Odds ratio; AOR, Adjusted odds ratio; LMIC, Low middle-income country; UMCI, Upper middle-income country;
HIC, High-income country.
a The adjusted R-square for the full model was 54·48%.
b Fertile Crescent includes: Iraq, Jordan, Lebanon, Palestine, and Syria.
c Gulf includes: Kuwait, Oman, Qatar, Saudi Arabia, and Unite Arab Emirates.
d Horn of Africa includes: Yemen and Sudan.
eMaghreb includes: Algeria, Libya, Morocco, and Tunisia.
f Income group was removed from the multivariable analysis because of collinearity.
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These ﬁndings suggest that the standard of infection
control in dialysis differs across countries and across
dialysis units within each country. They also indicate
that extensive improvement is needed to control
HCV transmission among HD patients. Fortunately,
improvements appear to be already taking place as
validated by the declining trend in prevalence. These
ﬁndings highlight further the importance of addres-
sing HCV infection and disease burden in HD
patients, especially considering the recent availability
and increasing affordability of DAAs for HCV treat-
ment [4], and that the number of patients undergoing
dialysis is rising rapidly with the aging of the popula-
tion and growing prevalence of chronic diseases that
lead to renal disease [40, 195–197].
Our pooled mean estimate for HCV prevalence
indicated that HCV prevalence among HD patients
in MENA is higher than that in other regions such
as Europe (7·2%) [198], the USA (7·9%) [199, 200],
and the Asia-Paciﬁc region (range across countries
of 1–18%) [201]. This ﬁnding may not only suggest
inferior standards of dialysis in MENA, but may
also reﬂect the higher background HCV prevalence
in the whole population in this region [2, 3]. Indeed,
HCV prevalence among HD patients in MENA coun-
tries reﬂected in part HCV prevalence in the popula-
tion at large in each country. For example, HCV
prevalence among HD patients in Egypt and
Pakistan was much higher than that in other MENA
countries (Table 5), reﬂecting the higher prevalence
in the wider population in these two countries [13, 22].
The high HCV incidence and prevalence in HD
patients appear to reﬂect improper application of
infection control measures, such as by healthcare per-
sonnel to maintain hands hygiene [199, 202], to
change gloves routinely [199, 202], and to clean the
dialysis unit and equipment properly between patients
[8, 203]. With the continuing conﬂict emergencies in
several countries and the large refugee and migrant
populations, overloading dialysis units and depletion
of medical resources is a growing concern [204, 205].
These emergencies appear to have led to reuse and
sharing of supplies and equipment intended for single
usage such as infusion vials and machine ﬁlters [205,
206]. The lingering emergencies may undermine the
recent improvements and reverse the trend of declin-
ing HCV prevalence in HD patients.
We found substantial diversity in the circulating
HCV genotypes in HD patients across countries.
However, this diversity appeared to reﬂect the distri-
bution of circulating genotypes in each countryT
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[207]. For example, the dominant genotypes among
HD patients in Egypt and Pakistan were genotypes
4 and 3, respectively (Table 6), similar to the domin-
ant genotypes in the wider population in these two
countries [207]. These ﬁndings may indicate overlap-
ping transmission networks where HCV is circulating
from one population to another through different
modes of exposure including dialysis.
A review of HCV among HD patients in the Middle
East has been recently published [208]. Its ﬁndings
agreed overall with our ﬁndings despite differences
between the two studies in the focus, scope, and analysis
plans. Our study covered more countries in MENA
over a longer duration, examined analytically trends
and associations, and reported a broader set of outcome
measures and analyses (such as for the genotype distri-
bution). In total, 205 studies were included in our ana-
lyses compared to 56 studies in Ashkani-Esfahani et al.
study [208]. Both studies concluded that there is high
HCV prevalence in HD patients that needs to be
addressed through targeted interventions.
Our study had several limitations. The availability
of data varied from one county to another and we
did not identify any data for ﬁve MENA countries
(Afghanistan, Bahrain, Djibouti, Mauritania, and
Somalia). Sample size varied also across studies and
the sampled HD populations may have been sampled
from speciﬁc geographic areas within a given country,
and may not be representative of the wider HD popu-
lation in the country. Despite these limitations, we
were able to identify a large volume of data for
MENA countries that allowed us to conduct different
types of analyses, generate multiple inferences, and
produce a comprehensive mapping of HCV epidemi-
ology among HD patients in this region.
CONCLUSIONS
Our ﬁndings revealed ongoing HCV incidence and high
HCV prevalence among HD patients in MENA, but
incidence and prevalence appear to be declining year
by year. About one-ﬁfth of HD patients are chronic
carriers of HCV infection, in need of HCV treatment,
and potentially can transmit the infection to other
HD patients. In context of rapidly growing HD patient
population, these ﬁndings highlight the need to improve
standards of infection control in dialysis in MENA.
Moreover, in context of recent availability and
increasing affordability of DAAs for HCV treatment,
these ﬁndings highlight the urgency to address HCV
infection and disease burden in HD patients.
Governments that are reluctant to take on national
level HCV elimination projects, could initially focus
on HD patients as a candidate population for micro-
elimination as a way to advance the agenda for
HCV DAA treatment. With HCV circulation among
HD patients being a major mode of HCV transmis-
sion, tackling this infection and disease burden is crit-
ical to HCV global elimination and mortality
reduction targets by 2030.
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